Bioethics News

The Other CRISPR Patent Dispute

August 31, 2016

(The Scientist) – As the biotech community has become fixated on a patent fight between the Broad Institute and the University of California (UC), Berkeley, over who can stake its claim to the revolutionary gene-editing technique that is CRISPR, another dispute has been quietly bubbling below the surface. At the center of this disagreement are two leaders in the field—the Broad’s Feng Zhang and Rockefeller University’s Luciano Marraffini—thrust into a strange circumstance involving a secretly filed patent application, an aggravated legal team, and a patent office facing an unorthodox situation.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.